CN1820789A - Biological degradable hemostatic sponge material and its preparing method - Google Patents
Biological degradable hemostatic sponge material and its preparing method Download PDFInfo
- Publication number
- CN1820789A CN1820789A CN 200610041913 CN200610041913A CN1820789A CN 1820789 A CN1820789 A CN 1820789A CN 200610041913 CN200610041913 CN 200610041913 CN 200610041913 A CN200610041913 A CN 200610041913A CN 1820789 A CN1820789 A CN 1820789A
- Authority
- CN
- China
- Prior art keywords
- collagen
- sponge material
- solution
- hemostatic sponge
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention discloses a kind of biodegradable hemostatic sponge material and its preparation process. The preparation process includes the following steps: 1. dissolving collagen like human collagen in distilled water to form 0.5-3 % concentration solution; 2. dissolving chitosan in dilute acid solution to form 0.5-2 % concentration solution and neutralizing with alkali; and 3. mixing the two kinds of obtained solution, vacuum defoaming and freeze drying to form sponge and Co-60 irradiating sterilization. The biodegradable hemostatic sponge material has high adhesion to tissue, less immune rejection, high toughness, excellent pain relieving and sterilizing effect, capability of promoting the recovery of damaged tissue, high hemostatic effect and greatly raised safety.
Description
Technical field
The present invention relates to a kind of biological degradable hemostatic sponge material and preparation method thereof, belong to biomedical materials field.
Background technology
Extensively hemorrhage and oozing of blood is to need the difficult problem that solves in surgical operation and the wound.
Collagen protein is that the animal body intensive amount is maximum, the widest protein distributes, be the primary structure albumen of body, be the key component of supporting tissue and connective tissue, it has excellent biological compatibility, anthemorrhagic performance, short new cell formation function and cell adhesion.Studies show that in recent years, collagen protein can stop blooding rapidly in 10 seconds, and can promote granulation growth and wound healing, prevents once more hemorrhage generation.
Human-like Collagen is after one section mRNA reverse transcription with human body known array collagen protein generates cDNA, repeat and modification through particular sequence, transform in escherichia coli, and get through high density fermentation, separation and Extraction and purification, invent and produce without competition by Xi'an giant's biological gene technical concern company limited.It has fundamentally solved the water-insoluble and the viral hidden danger problems such as (bovine spongiform encephalopathy, swine fever epidemic disease, bird flus) of animal extraction collagen protein, and have good biological characteristics and function, short new cell forms and urgees epithelial cell, fibroblastic growth function, it is good to compare animal body extraction collagen protein, and immune rejection is low.
Chitin is the natural macromolecular material that extracts from the cell wall of the shell of Crustaceans such as shrimp, Eriocheir sinensis and bacterium, algae rudimentary plant, and chitosan is the deacetylated product of chitin, is the unique alkaline polysaccharide of occurring in nature.Studies show that in recent years, chitosan have excellent performances such as pain relieving, hemostasis, antibacterial, excellent biological compatibility and biodegradability, are very suitable for the raw material as hemostatic material.
The toughness of simple gelfoam or collagen haemostatic sponge is relatively poor, and does not have pain relieving and antibacterial effect, as Chinese patent CN200410022462.X and CN 01133795.8; The promoting growth of cell of simple chitosan sponge and short organized renewing ability a little less than, have hemorrhage once more possibility.Can effectively overcome above shortcoming to the compound sthptic sponge of collagen protein-chitosan that both combine at present, as patent application CN 02109638.4, but there is viral hidden danger simultaneously in it and promotes that wound recovers shortcoming slowly.Research for sthptic sponge also mainly concentrates on collagen protein and modification aspect thereof in the world, as patent US 6649162, AU 726163B and RU 2122867, what but they used all is that traditional animal is extracted collagen protein, also inevitably exist viral hidden danger, limited the application of this sthptic sponge greatly.
Summary of the invention
One of purpose of the present invention provides a kind of biodegradable hemostatic sponge material that Human-like Collagen and chitosan are combined, and to overcome gelatin and the inevitable viral hidden danger of animal collagen sponge, improves the safety of hemostatic sponge material.
Another object of the present invention provides the preparation method of above-mentioned biodegradable hemostatic sponge material, and this method technology is simple.
Biological degradable hemostatic sponge material of the present invention is to be made by Human-like Collagen and chitosan, the weight ratio of Human-like Collagen and chitosan can be (1～40): 1, optimal proportion is (3～40): 1, and a kind of people source collagen type of used Human-like Collagen for using the gene recombined escherichia coli high density fermentation to produce; The deacetylation of used chitosan is 50%～90%.
Biological degradable hemostatic sponge material preparation methods is as follows: (1) becomes Human-like Collagen 0.5%～3% solution with dissolved in distilled water; (2) chitosan is dissolved into 0.5%～2% solution with diluted acid, and uses the alkali neutralization; (3) with above-mentioned two kinds of solution mix homogeneously,, form sponge after the lyophilization, cobalt through vacuum defoamation
60Get final product behind the illumination-based disinfection.
In the above-mentioned preparation method, the weight ratio of Human-like Collagen and chitosan is (1～40): 1.A kind of people source collagen type of used Human-like Collagen for using the gene recombined escherichia coli high density fermentation to produce; The degree of deacetylation of used chitosan is 50%～90%.
In the above-mentioned preparation method, used diluted acid is any one in dilute hydrochloric acid, spirit of vinegar, dilute formic acid or the rare propanoic acid, and concentration can be 0.2～0.8moL/L; Used alkali is any one in diluted sodium hydroxide solution, rare potassium hydroxide solution or the sodium bicarbonate solution, and concentration can be 0.05～0.5moL/L.
In the above-mentioned preparation method, also added percentage by weight and be 0.1%～0.5% plasticizer in Human-like Collagen and chitosan mixed solution, described plasticizer is one or both in glycerol or the 1.3-butanediol.
In the above-mentioned preparation method, in Human-like Collagen and chitosan mixed solution, also added percentage by weight and be 0.1%～0.5% thrombin.
Biological degradable hemostatic sponge provided by the present invention compared with prior art, have tangible technological merit and advantage: this sthptic sponge and tissue adherence are good, the immunity rejection is low, toughness is strong, have good pain relieving and anti-microbial property, promote that the wounded tissue recovery capability is strong, can prevent once more hemorrhage possibility, thoroughly stopped gelatin and the inevitable viral hidden danger of animal collagen, safety in utilization increases substantially.
The specific embodiment
The invention will be further described below by concrete embodiment.
Embodiment 1:
Human-like Collagen become 1.0% solution with dissolved in distilled water; With deacetylation be 90%, to be 10000 daltonian chitosans become 0.5% solution with the acetate dissolution of 0.2moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.1moL/L; Then with the two 20: 1 by volume mix homogeneously, and add 0.2% glycerol, be sub-packed in the container; Become the thick sponge of 2mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 2:
Human-like Collagen become 1.0% solution with dissolved in distilled water; With deacetylation be 90%, to be 10000 daltonian chitosans become 0.5% solution with the acetate dissolution of 0.2moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.1moL/L; Then with the two 10: 1 by volume mix homogeneously, and add 0.2% glycerol and 0.3% thrombin, be sub-packed in the container; Become the thick sponge of 2mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 3:
Human-like Collagen become 2.0% solution with dissolved in distilled water; With deacetylation be 90%, to be 10000 daltonian chitosans become 1.0% solution with the acetate dissolution of 0.2moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.1moL/L; Then with the two 15: 1 by volume mix homogeneously, and add 0.2% glycerol, be sub-packed in the container; Become the thick sponge of 1.5mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 4:
Human-like Collagen become 2.0% solution with dissolved in distilled water; With deacetylation be 90%, to be 10000 daltonian chitosans become 1.0% solution with the acetate dissolution of 0.2moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.1moL/L; Then with the two 8: 1 by volume mix homogeneously, and add 0.2% glycerol and 0.2% thrombin, be sub-packed in the container; Become the thick sponge of 1.5mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 5:
Human-like Collagen become 1.0% solution with dissolved in distilled water; With deacetylation be 75%, to be 100000 daltonian chitosans become 0.5% solution with the acetate dissolution of 0.3moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.2moL/L; Then with the two 10: 1 by volume mix homogeneously, and add 0.4% 1.3-butanediol, be sub-packed in the container; Become the thick sponge of 2mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 6:
Human-like Collagen become 1.0% solution with dissolved in distilled water; With deacetylation be 75%, to be 100000 daltonian chitosans become 0.5% solution with the acetate dissolution of 0.3moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.2moL/L; Then with the two 6: 1 by volume mix homogeneously, and add 0.4% 1.3-butanediol and 0.3% thrombin, be sub-packed in the container; Become the thick sponge of 2mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 7:
Human-like Collagen become 2.0% solution with dissolved in distilled water; With deacetylation be 75%, to be 100000 daltonian chitosans become 1.0% solution with the acetate dissolution of 0.3moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.2moL/L; Then with the two 6: 1 by volume mix homogeneously, and add 0.4% 1.3-butanediol, be sub-packed in the container; Become the thick sponge of 1.5mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 8:
Human-like Collagen become 2.0% solution with dissolved in distilled water; With deacetylation be 75%, to be 100000 daltonian chitosans become 1.0% solution with the acetate dissolution of 0.3moL/L to molecular weight, and uses the sodium bicarbonate solution neutralization of 0.2moL/L; Then with the two 4: 1 by volume mix homogeneously, and add 0.2% glycerol, 0.2% 1.3-butanediol and 0.2% thrombin are sub-packed in the container; Become the thick sponge of 1.5mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 9:
Human-like Collagen become 1.0% solution with dissolved in distilled water; With deacetylation be 55%, to be 400000 daltonian chitosans become 0.5% solution with the dissolving with hydrochloric acid of 0.5moL/L to molecular weight, and uses the sodium hydroxide sodium solution neutralization of 0.1moL/L; Then with the two 5: 1 by volume mix homogeneously, and add 0.3% glycerol, be sub-packed in the container; Become the thick sponge of 2mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 10:
Human-like Collagen become 1.0% solution with dissolved in distilled water; With deacetylation be 55%, to be 400000 daltonian chitosans become 0.5% solution with the dissolving with hydrochloric acid of 0.5moL/L to molecular weight, and uses the sodium hydroxide sodium solution neutralization of 0.1moL/L; Then with the two 2: 1 by volume mix homogeneously, and add 0.3% glycerol and 0.3% thrombin, be sub-packed in the container; Become the thick sponge of 2mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 11:
Human-like Collagen become 2.0% solution with dissolved in distilled water; With deacetylation be 55%, to be 400000 daltonian chitosans become 1.0% solution with the dissolving with hydrochloric acid of 0.5moL/L to molecular weight, and uses the sodium hydroxide sodium solution neutralization of 0.1moL/L; Then with the two 3: 1 by volume mix homogeneously, and add 0.3% glycerol, be sub-packed in the container; Become the thick sponge of 1.5mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Embodiment 12:
Human-like Collagen become 2.0% solution with dissolved in distilled water; With deacetylation be 55%, to be 400000 daltonian chitosans become 1.0% solution with the dissolving with hydrochloric acid of 0.5moL/L to molecular weight, and uses the sodium hydroxide sodium solution neutralization of 0.1moL/L; Then with the two 1: 1 by volume mix homogeneously, and add 0.3% glycerol and 0.3% thrombin, be sub-packed in the container; Become the thick sponge of 1.5mm through the vacuum defoamation postlyophilization; Cobalt
60Get final product behind the illumination-based disinfection.
Claims (9)
1. biological degradable hemostatic sponge material is characterized in that: the weight ratio of Human-like Collagen and chitosan is (1～40): 1.
2. biological degradable hemostatic sponge material according to claim 1 is characterized in that: a kind of people source collagen type of Human-like Collagen for using the gene recombined escherichia coli high density fermentation to produce.
3. biological degradable hemostatic sponge material according to claim 1 is characterized in that: the deacetylation of used chitosan is 50%～90%.
4. the described biological degradable hemostatic sponge material of claim 1 preparation methods is characterized in that:
(1) Human-like Collagen is become 0.5%～3% solution with dissolved in distilled water;
(2) chitosan is dissolved into 0.5%～2% solution with diluted acid, and uses the alkali neutralization;
(3) with above-mentioned two kinds of solution mix homogeneously,, form sponge after the lyophilization, cobalt through vacuum defoamation
60Get final product behind the illumination-based disinfection.
5. biological degradable hemostatic sponge material preparation methods according to claim 4 is characterized in that: the weight ratio of Human-like Collagen and chitosan is (1～40): 1.
6. biological degradable hemostatic sponge material preparation methods according to claim 4 is characterized in that: used diluted acid is any one in dilute hydrochloric acid, spirit of vinegar, dilute formic acid or the rare propanoic acid; Used alkali is any one in diluted sodium hydroxide solution, rare potassium hydroxide solution or the sodium bicarbonate solution.
7. according to claim 4,5 or 6 one of any described biological degradable hemostatic sponge material preparation methods, it is characterized in that: in Human-like Collagen and chitosan mixed solution, also added percentage by weight and be 0.1%～0.5% plasticizer.
8. biological degradable hemostatic sponge material preparation methods according to claim 7 is characterized in that: described plasticizer is one or both in glycerol or the 1.3-butanediol.
9. according to claim 4,5 or 6 one of any described biological degradable hemostatic sponge material preparation methods, it is characterized in that: in Human-like Collagen and chitosan mixed solution, also added percentage by weight and be 0.1%～0.5% thrombin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100419133A CN100415304C (en) | 2006-03-13 | 2006-03-13 | Biological degradable hemostatic sponge material and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100419133A CN100415304C (en) | 2006-03-13 | 2006-03-13 | Biological degradable hemostatic sponge material and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1820789A true CN1820789A (en) | 2006-08-23 |
| CN100415304C CN100415304C (en) | 2008-09-03 |
Family
ID=36922458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100419133A Active CN100415304C (en) | 2006-03-13 | 2006-03-13 | Biological degradable hemostatic sponge material and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100415304C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028543B (en) * | 2007-04-03 | 2010-05-26 | 哈尔滨工业大学 | Degradable sebacic acid and propyl tri-alcohol ester styptic sponge and its preparation |
| CN102258802A (en) * | 2010-05-28 | 2011-11-30 | 朱楚洪 | Novel multifunctional hemostatic dressing |
| CN102526795A (en) * | 2012-02-15 | 2012-07-04 | 中国人民解放军***武汉总医院 | Chitosan-based styptic sponge and preparation method thereof |
| CN102600495A (en) * | 2011-01-19 | 2012-07-25 | 北京博恩康生物科技有限公司 | Absorbable hemostatic composition and preparation method thereof |
| US9028872B2 (en) | 2006-03-01 | 2015-05-12 | Fmc Corporation | Gelled composite |
| CN105903066A (en) * | 2016-07-02 | 2016-08-31 | 河南驼人贝斯特医疗器械有限公司 | Preparation method of absorbable and degradable in-vivo hemostatic sponge |
| CN106512075A (en) * | 2016-12-02 | 2017-03-22 | 上海其胜生物制剂有限公司 | Preparation method of high-expansion lamella porous chitosan hemostatic sponge |
| CN110368518A (en) * | 2019-03-19 | 2019-10-25 | 易杨华 | Rubidium salt styptic sponge and its application |
| CN113842494A (en) * | 2021-09-10 | 2021-12-28 | 西北大学 | Injectable hemostatic crystal gel for promoting tissue regeneration and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020015724A1 (en) * | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
| CN1234424C (en) * | 2001-09-10 | 2006-01-04 | 中国人民解放军军事医学科学院卫生装备研究所 | Collagen based composite sponge and production thereof |
| CN1387922A (en) * | 2002-04-30 | 2003-01-01 | 岳武 | Quick-hemagglutination hemostasis sponge |
| CN1217706C (en) * | 2003-08-22 | 2005-09-07 | 北京益而康生物工程开发中心 | Prepration process for biologic hemostatic sponge material |
-
2006
- 2006-03-13 CN CNB2006100419133A patent/CN100415304C/en active Active
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9028872B2 (en) | 2006-03-01 | 2015-05-12 | Fmc Corporation | Gelled composite |
| CN101028543B (en) * | 2007-04-03 | 2010-05-26 | 哈尔滨工业大学 | Degradable sebacic acid and propyl tri-alcohol ester styptic sponge and its preparation |
| CN102258802A (en) * | 2010-05-28 | 2011-11-30 | 朱楚洪 | Novel multifunctional hemostatic dressing |
| CN102258802B (en) * | 2010-05-28 | 2016-01-27 | 朱楚洪 | A kind of Novel multifunctional hemostatic dressing |
| CN102600495A (en) * | 2011-01-19 | 2012-07-25 | 北京博恩康生物科技有限公司 | Absorbable hemostatic composition and preparation method thereof |
| CN102526795A (en) * | 2012-02-15 | 2012-07-04 | 中国人民解放军***武汉总医院 | Chitosan-based styptic sponge and preparation method thereof |
| CN105903066A (en) * | 2016-07-02 | 2016-08-31 | 河南驼人贝斯特医疗器械有限公司 | Preparation method of absorbable and degradable in-vivo hemostatic sponge |
| CN106512075A (en) * | 2016-12-02 | 2017-03-22 | 上海其胜生物制剂有限公司 | Preparation method of high-expansion lamella porous chitosan hemostatic sponge |
| CN110368518A (en) * | 2019-03-19 | 2019-10-25 | 易杨华 | Rubidium salt styptic sponge and its application |
| CN113842494A (en) * | 2021-09-10 | 2021-12-28 | 西北大学 | Injectable hemostatic crystal gel for promoting tissue regeneration and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100415304C (en) | 2008-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1820789A (en) | Biological degradable hemostatic sponge material and its preparing method | |
| CN1820790A (en) | Method for preparing biological degradable tissue engineering rack material | |
| CN100463673C (en) | Compound medicine release controlling film of chitosan, sodium alginate and gelatin and its preparing process | |
| Azuma et al. | Preparation and biomedical applications of chitin and chitosan nanofibers | |
| US9078949B2 (en) | Compositions of partially deacetylated chitin derivatives | |
| Hon | Chitin and chitosan: medical applications | |
| JP2004018757A (en) | Biodegradable biopolymer material, method for producing the same and functional material composed of the polymer material | |
| JPH10502665A (en) | Wound healing agent | |
| CN1234424C (en) | Collagen based composite sponge and production thereof | |
| CN101002957A (en) | Biodegradable quick hemostyptic dressing, and its preparing method | |
| CN102526795A (en) | Chitosan-based styptic sponge and preparation method thereof | |
| CN1546181A (en) | Degradable material capable of guiding the regeneration and renovation process of hard tissue and its preparation | |
| CN101053669A (en) | Water soluble chitosan-based hemostatic wound-healing marine sponge and its preparation method and application | |
| CN110152055B (en) | Functional drug sustained-release medical dressing constructed by alginic acid aminated derivative/bacterial cellulose nanocrystalline composite gel | |
| JP2010053080A (en) | Structure containing chitosan and collagen | |
| Wei et al. | Facile preparation of polysaccharides-based adhesive hydrogel with antibacterial and antioxidant properties for promoting wound healing | |
| CN1670061A (en) | Carboxymerhyl chitosan sponge with water-absorbent dilatability and its preparation method and use thereof | |
| CN112341640A (en) | Bio-based self-repairing hydrogel and preparation method and application thereof | |
| CN101074271A (en) | Production and use for amphipathic chitose derivative | |
| He et al. | Hemostatic, antibacterial and degradable performance of the water-soluble chitosan-coated oxidized regenerated cellulose gauze | |
| CN111375085A (en) | Fluid hemostatic gel and preparation method thereof | |
| CN110624509A (en) | Preparation method of porous composite material based on graphene oxide and chitosan | |
| CN1485097A (en) | Prepration process for biologic hemostatic sponge material | |
| CN100525778C (en) | Novel post-operation antiadhesive materials and its preparation method | |
| CN1179755C (en) | Medical collagen sponge and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |